Lenalidomide,Bortezomib,Dexamethasone
Takeda
determination: among mrd negative regardless of rx outcomes similar. he shows that sct more likely to be of benefit for hr. also showed t(11;14) may benefit too. low numbers in subgroups but consistent with larger body of data. mds/aml only with sct arm
#ims2022 #mmsm 
Chief Innovation Officer - Mayo Clinic in Arizona. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement